natgillin/translations-raw huggingface dataset:
Following single dose lamivudine/zidovudine administration in healthy volunteers, mean (CV) lamivudine and zidovudine Cmax values were 1.6 µg/ml (32 %) and 2.0 µg/ml (40 %), respectively and the corresponding values for AUC were 6.1 µg h/ml (20 %) and 2.4 µg h/ml (29 %) respectively.
Po zaužitju enkratnega odmerka zdravila Lamivudin/zidovudin Teva so pri zdravih prostovoljcih srednje (CV) vrednosti Cmax lamivudina znašale 1,6 μg/ml (32 %) in zidovudina 2,0 μg/ml (40 %), pripadajoče vrednosti površine pod krivuljo (AUC) pa so bile 6,1 μg h/ml (20 %) oziroma 2,4 μg h/ml (29 %).
Following single dose, oral administration of 1.5 g of mycophenolate mofetil to normal healthy subjects pre-treated with 4 g TID of cholestyramine for 4 days, there was a 40% reduction in the AUC of MPA (see section 4.4, and section 5.2).
Če dajemo holestiramin 4 dni v odmerku 4 g trikrat na dan, ta zmanjša AUC mikofenolne kisline po enkratnem peroralnem vnosu 1,5 g mofetilmikofenolata za približno 40 % (glejte poglavje 4.4 in poglavje 5.2).
Following single doses of [cyano-14C] isavuconazonium and [pyridinylmethyl-14C] isavuconazonium sulfate in humans, in addition to the active moiety (isavuconazole) and the inactive cleavage product, a number of minor metabolites were identified.
Po enkratnem odmerku [ciano-14C] izavukonazonijevega in [piridinilmetil-14C] izavukonazonijevega sulfata pri ljudeh, je razen aktivne spojine (izavukonazola) in neaktivnega produkta cepitve prepoznanih več manj pomembnih metabolitov.
Following single intramuscular doses of 0.4 mg meloxicam/kg, a Cmax value of 1.1 to 1.5 μg/ml was reached within 1 hour in pigs.
Po enkratnih intramuskularnih odmerkih meloksikama po 0,4 mg/kg je Cmax pri prašičih po 1 uri znašala 1,1 do 1,5 g/ml.
Following single IV and IM doses of parecoxib 20 mg, Cmax of valdecoxib is achieved in approximately 30 minutes and approximately 1 hour, respectively.
Po enkratnih i.v. ali i.m. odmerkih 20 mg parekoksiba je Cmax valdekoksiba dosežena v približno 30 minutah (i.v.) oz. približno 1 uri (i.m.).
Following single oral 100 mg dose in subjects with varying degrees of liver impairment and healthy subjects, eluxadoline plasma levels were on average 6-fold, 4-fold, and 16-fold elevated in mild, moderate, and severe hepaticimpaired subjects (Child Pugh Class A, B, C), respectively, while half-life increased 3-5 fold (see sections 4.3 and 4.4).
Po enkratnem peroralnem odmerku 100 mg pri osebah z različnimi stopnjami okvare jeter in pri zdravih osebah so bile plazemske koncentracije eluksadolina v povprečju za 6-krat, 4-krat in 16-krat povišane pri osebah z blago, zmerno in hudo okvaro jeter (razredi Child Pugh A, B, C), medtem ko je bil razpolovni čas za 3- do 5-krat daljši (glejte poglavji 4.3 in 4.4).
Following single oral administration of [14C] fingolimod, the major fingolimod-related components in blood, as judged from their contribution to the AUC up to 34 days post dose of total radiolabelled components, are fingolimod itself (23%), fingolimod phosphate (10%), and inactive metabolites (M3 carboxylic acid metabolite (8%), M29 ceramide metabolite (9%) and M30 ceramide metabolite (7%)).
Po enem samem peroralnem odmerku s C14 označenega fingolimoda so najbolj pomembne s fingolimodom povezane sestavine v krvi, sodeč po njihovem deležu pri AUC po 34 dneh po odmerjanju v celoti radioaktivno označenih sestavin: sam fingolimod (23 %), fingolimodijev fosfat (10 %) in neaktivni metaboliti (M3 metabolit s karboksilno kislino (8 %), M29 ceramidni metabolit (9 %) in M30 ceramidni metabolit (7 %)).
Following single oral administration of naltrexone / bupropion tablets to healthy subjects, peak concentrations of naltrexone and bupropion occurred approximately 2 and 3 hours post administration of naltrexone / bupropion, respectively.
Po enkratni peroralni aplikaciji tablet kombinacije naltrekson/bupropion pri zdravih preiskovancih so bile največje koncentracije naltreksona oziroma bupropiona dosežene približno 2 oziroma 3 ure po aplikaciji kombinacije naltrekson/bupropion.
Following single oral doses of ceritinib, the geometric mean apparent plasma terminal half-life (T½) of ceritinib ranged from 31 to 41 hours in patients over the 400 to 750 mg dose range.
Po peroralnem odmerjanju enkratnih odmerkov ceritiniba bolnikom je geometrična srednja vrednost navideznega končnega razpolovnega časa izločanja iz plazme (T½) znašala od 31 do 41 ur v razponu odmerkov od 400 do 750 mg.
Following single oral doses of  300 mg, peak plasma concentrations appear to plateau, possibly due to saturation of absorption.
Po enkratnih peroralnih odmerkih  300 mg so se najvišje koncentracije v plazmi približale platoju, mogoče zaradi nasičenosti absorpcije.
Following single oral doses of  300 mg, peak plasma concentrations appear to plateau, possibly due to saturation of absorption.
Po enojnih peroralnih odmerkih  300 mg so se najvišje koncentracije v plazmi približale platoju, mogoče zaradi nasičenosti absorpcije.
Following single-dose oral administration of 14C–daclatasvir in healthy subjects, 88% of total radioactivity was recovered in feces (53% as unchanged drug) and 6.6% was excreted in the urine (primarily as unchanged drug).
Po enkratnem peroralnem odmerku z radioaktivnim izotopom 14C označenega daklatasvirja se je pri zdravih osebah 88 % celotne radioaktivnosti izločilo z blatom (53 % v obliki nespremenjenega zdravila), 6,6 % pa z urinom (v glavnem v nespremenjeni obliki).
Following subcutaneous administration in dogs a transient swelling (up to 5 cm) may commonly be observed at the injection site.
Po subkutanem dajanju se lahko na mestu dajanja pri psih pogosto pojavi prehodna oteklina (do 5 cm).
Following subcutaneous administration in dogs a transient swelling (up to 5 cm) may commonly be observed at the injection site.
Po subkutani aplikaciji se lahko na mestu cepljenja pri psih pogosto pojavi prehodna oteklina (do 5 cm).
Following subcutaneous administration in dogs a transient swelling (up to 5 cm) may commonly be observed at the injection site.
Po subkutani aplikaciji se lahko na mestu vakcinacije pri psih pogosto pojavi prehodna oteklina (do 5 cm).
Following subcutaneous administration in dogs, a transient swelling (up to 5 cm), may commonly be observed at the injection site.
Po subkutanem dajanju se lahko na mestu injiciranja pri psih pogosto pojavi prehodna oteklina (do 5 cm).
Following subcutaneous administration in dogs, a transient swelling (up to 5 cm), may commonly be observed at the injection site.
Po subkutani aplikaciji se lahko na mestu cepljenja pri psih pogosto pojavi prehodna oteklina (do 5 cm).
Following subcutaneous administration of 240 mg degarelix at a concentration of 40 mg/ml to prostate cancer patients in the pivotal study CS21, AUC0-28 days was 635 (602-668) day*ng/ml, Cmax was 66.0 (61.0- 71.0) ng/ml and occurred at tmax at 40 (37-42) hours.
Po subkutani aplikaciji 240 mg degareliksa v koncentraciji 40 mg/ml bolnikom z rakom prostate v ključni študiji CS21 je bila AUC0-28 dni 635 (602-668) dan*ng/ml, Cmax je bila 66,0 (61,0-71,0) ng/ml, nastopila pa je ob tmax 40 (37-42) ur.
Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoid arthritis (RA) patients the mean steady-state trough concentrations were approximately 5 g/ml (without concomitant methotrexate) and 8 to 9 g/ml (with concomitant methotrexate), respectively.
Po subkutani uporabi 40 mg adalimumab vsak drugi teden pri odraslih bolnikih z revmatoidnim artritisom (RA) so bile povprečne najmanjše koncentracije v stanju dinamičnega ravnovesja približno 5 μg/ml (brez sočasne uporabe metotreksata) in od 8 do 9 μg/ml (s sočasno uporabo metotreksata).
Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoid arthritis (RA) patients the mean steady-state trough concentrations were approximately 5 g/ml (without concomitant methotrexate) and 8 to 9 g/ml (with concomitant methotrexate), respectively.
Po subkutani uporabi 40 mg adalimumaba vsak drugi teden pri odraslih bolnikih z revmatoidnim artritisom (RA) so bile povprečne najmanjše koncentracije v stanju dinamičnega ravnovesja približno 5 μg/ml (brez sočasne uporabe metotreksata) in od 8 do 9 μg/ml (s sočasno uporabo metotreksata).
Following subcutaneous administration of 40 mg of Trudexa every other week in rheumatoid arthritis (RA) patients the mean steady-state trough concentrations were approximately 5 g/ml (without concomitant methotrexate) and 8 to 9 g/ml (with concomitant methotrexate), respectively.
Po subkutani uporabi 40 mg Trudexe vsak drugi teden pri bolnikih z revmatoidnim artritisom (RA) so bile povprečne najmanjše koncentracije v stanju dinamičnega ravnovesja približno 5 µg/ml (brez sočasne uporabe metotreksata) in od 8 do 9 µg/ml (s sočasno uporabo metotreksata).
Following subcutaneous administration of a single 75 mg/m2 dose, azacitidine was rapidly absorbed with peak plasma concentrations of 750 ± 403 ng/mL occurring at 0.5 h after dosing (the first sampling point).
Po subkutanem dajanju enkratnega odmerka 75 mg/m2 se je azacitidin hitro absorbiral z najvišjimi koncentracijami v plazmi 750 ± 403 ng/ml, ki so se pojavile 0,5 ure po injiciranju (prva točka vzorčenja).
Following subcutaneous administration of a single 75 mg/m2 dose, mean exposure values (AUC and Cmax) from subjects with mild, moderate and severe renal impairment were increased by 11-21%, 15-27%, and 41-66%, respectively, compared to normal renal function subjects.
Po subkutanem dajanju enkratnega odmerka 75 mg/m2 so se srednje vrednosti izpostavljenosti (AUC in Cmax) oseb z blago, zmerno in hudo okvaro ledvic zvečale za 11-21 %, 15-27 % oziroma 41-66 % v primerjavi z osebami z normalno ledvično funkcijo.
Following subcutaneous administration of Hizentra, peak serum levels are achieved after approximately 2 days.
Po subkutanem dajanju zdravila Hizentra se najvišje serumske ravni dosežejo po približno 2 dneh.
Following subcutaneous administration of HyQvia, peak serum IgG levels are achieved in the recipient’s circulation after approximately 3 to 5 days.
Po subkutanem dajanju zdravila HyQvia se najvišje serumske koncentracije IgG v krvnem obtoku pojavijo po približno 3 do 5 dneh.
Following subcutaneous administration of Luveris, lutropin alfa is eliminated from the body with a terminal half-life of about 10-12 hours.
Po subkutanem dajanju zdravila Luveris se lutropin alfa izloči iz telesa s končnim razpolovnim časom približno 10–12 ur.
Following subcutaneous administration of recommended doses, serum concentrations were maintained above 10 ng/ml for 8 - 16 hours.
Po subkutanem dajanju priporočenega odmerka, se je serumska koncentracija vzdrževala nad vrednostjo 10 ng/ml 8 – 16 ur.
Following subcutaneous administration of recommended doses, serum concentrations were maintained above10 ng/ml for 8 - 16 hours.
Po podkožnem dajanju priporočenega odmerka se je serumska koncentracija vzdrževala nad vrednostjo 10 ng/ml 8 do 16 ur.
Following subcutaneous administration of the implant, most of the active substance is released within the first 48 hours with over 90% released by Day 5.
Po subkutani uporabi implantata se večina zdravilne učinkovine sprosti v prvih 48 urah, do 5. dneva pa 90 %.
Following subcutaneous administration to patients with type 2 diabetes, dulaglutide reaches peak plasma concentrations in 48 hours.
Po subkutani aplikaciji bolnikom s sladkorno boleznijo tipa 2 dulaglutid doseže najvišje koncentracije v plazmi v 48 urah.
Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2 h.
Po subkutanem dajanju eksenatida bolnikom z diabetesom tipa 2, doseže eksenatid mediano najvišje plazemske koncentracije v 2 urah.
Following subcutaneous administration, choriogonadotropin alfa is eliminated from the body with a terminal halflife of about 30 hours, and the absolute bioavailability is about 40%.
Po subkutani uporabi se horiogonadotropin alfa izloča iz telesa s končnim razpolovnim časom približno 30 ur, absolutna biološka razpoložljivost pa je približno 40 %.
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 µg/ml in dogs and 1.1 µg/ml in cats were reached approximately
Meloksikam je po podkožnem dajanju v celoti biološko uporaben in doseže največjo srednjo koncentracijo v plazmi, ki je 0,73 µg/ml pri psih in 1,1 µg/ml pri mačkah, približno 2,5 ure oz.
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 g/ml in dogs and 1.1 µg/ml in cats were reached approximately
Meloksikam je po podkožnem dajanju v celoti biološko uporaben in doseže največjo srednjo koncentracijo v plazmi, ki je 0,73 µg/ml pri psih in 1,1 µg/ml pri mačkah, približno 2,5 ure oz.
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 g/ml in dogs and 1.1 µg/ml in cats were reached approximately 2.5 hours and
Meloksikam je po podkožnem dajanju v celoti biološko uporaben in doseže največjo srednjo koncentracijo v plazmi, ki je 0,73 µg/ml pri psih in 1,1 µg/ml pri mačkah, približno 2,5 ure oz.
Following subcutaneous administration, similar Cmax of teduglutide across age groups was demonstrated by population pharmacokinetics modeling.
Po subkutanem dajanju so s populacijskim farmakokinetičnim moduliranjem dokazali podobno Cmax teduglutida po starostnih skupinah.
Following subcutaneous administration, teduglutide has an apparent volume of distribution of 26 litres in patients with SBS.
Po subkutani uporabi ima teduglutid pri bolnikih s SKČ navidezni volumen porazdelitve 26 litrov.
Following subcutaneous administration, the absolute bioavailability is approximately 60 %.
Po subkutani uporabi je absolutna biološka razpoložljivost približno 60 %.
Following subcutaneous administration, the absolute bioavailability of icatibant is 97%.
Po subkutani aplikaciji je absolutna biološka uporabnost ikatibanta 97 %.
Following subcutaneous administration, the protracted action profile is based on three mechanisms: self­association, which results in slow absorption; binding to albumin; and higher enzymatic stability towards the dipeptidyl peptidase ­4 (DPP­4) and neutral endopeptidase (NEP) enzymes, resulting in a long plasma half­life.
Podaljšano delovanje zdravila po subkutani aplikaciji temelji na treh mehanizmih: samozdruževanju, ki upočasni absorpcijo, vezavi na albumin ter večji stabilnosti proti delovanju dipeptidil peptidaze 4 (DPP-4) in nevtralne endopeptidaze, kar povzroči dolg razpolovni čas v plazmi.
Following subcutaneous dosing in patients with asthma, mepolizumab exhibited approximately dose- proportional pharmacokinetics over a dose range of 12.5 mg to 250 mg.
Pri bolnikih z astmo je imel subkutano uporabljeni mepolizumab v odmerkih od 12,5 mg do 250 mg približno odmerku sorazmerno farmakokinetiko.
Following subcutaneous dosing in RA patients, the time to peak serum tocilizumab concentrations tmax was 2.8 days.
Po subkutanem odmerjanju pri bolnikih z revmatoidnim artritisom je bil čas do največje serumske koncentracije tocilizumaba tmax 2,8 dni.
Following subcutaneous injection, serum levels of erythropoietin are much lower than the levels achieved following intravenous injection, the levels increase slowly and reach a peak between 12 and 18 hours postdose.
Po subkutani injekciji so koncentracije eritropoetina v serumu veliko nižje kot pa je to primer pri intravenskih injekcijah. koncentracije počasi rastejo in dosežejo vrh med 12 in 18 urami po odmerjanju.
Following surgery all patients received 3 cycles of 5- fluorouracil (600 mg/m2), epirubicin (90 mg/m2), cyclophosphamide (600 mg/m2) (FEC) given intravenously every three weeks, and trastuzumab administered intravenously every three weeks to complete one year of therapy.
Po operaciji so vse bolnice prejele 3 cikle kombinacije 5-fluorouracila (600 mg/m2), epirubicina (90 mg/m2) in ciklofosfamida (600 mg/m2) (FEC) intravensko vsake tri tedne in trastuzumab intravensko vsake tri tedne do zaključka enoletnega zdravljenja.
Following surgery, patients should be treated with adjuvant trastuzumab to complete 1 year of treatment (see section 5.1).
Po operaciji morajo bolniki prejeti adjuvantno zdravljenje s trastuzumabom do zaključka 1-letnega zdravljenja (glejte poglavje 5.1).
Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50 % within 1 to 2 days, and to normal levels within 1 to 7 days.
1. ali 2. dan po koncu zdravljenja s filgrastimom število nevtrofilcev v obtoku pade za 50 %, na običajno raven pa se povrne v obdobju od 1 do 7 dni.
Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.
1. ali 2. dan po koncu zdravljenja s filgrastimom število nevtrofilcev v obtoku pade za 50%, na običajno raven pa se povrne v obdobju od 1 do 7 dni.
Following the administration of 0.8 mg/kg (up to a maximum of 40 mg) subcutaneously every other week to paediatric patients with chronic plaque psoriasis, the mean ± SD steady-state adalimumab trough concentration was approximately 7.4 ± 5.8 µg/mL (79% CV).
Po dajanju adalimumaba 0,8 mg/kg (do največ 40 mg) subkutano vsak drugi teden pediatričnim bolnikom s kronično psoriazo v plakih so bile srednje koncentracije adalimumaba v stanju dinamičnega ravnovesja približno 7,4 ± 5,8 µg/ml (79 % KV).
Following the administration of 160 mg 14C-mirabegron to healthy volunteers, approximately 55% of the radiolabel was recovered in the urine and 34% in the faeces.
Po uporabi 160 mg 14C-mirabegrona pri zdravih prostovoljcih se je pribliţno 55 % radioaktivnosti pojavilo v urinu in 34 % v blatu.
Following the administration of 24 mg/m2 (up to a maximum of 40 mg) subcutaneously every other week to patients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (values measured at Week 24) serum adalimumab concentrations were 8.8 ± 6.6 μg/mL for adalimumab without concomitant methotrexate and 11.8 ± 4.3 μg/mL with concomitant methotrexate.
Po dajanju 24 mg/m2 (do največ 40 mg) subkutano vsak drugi teden bolnikom z artritisom, povezanim z entezitisom, ki so bili stari od 6 do 17 let, je bila povprečna najmanjša koncentracija adalimumaba v serumu v stanju dinamičnega ravnovesja (vrednost merjena v 24. tednu) 8,8 ± 6,6 μg/ml med uporabo adalimumaba brez metotreksata in 11,8 ± 4,3 μg/ml med sočasno uporabo metotreksata.
Following the administration of 24 mg/m2 (up to a maximum of 40 mg) subcutaneously every other week to patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17 years the mean trough steady-state (values measured from Week 20 to 48) serum adalimumab concentration was 5.6
Po uporabi 24 mg/m2 (do največ 40 mg) subkutano vsak drugi teden pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom (JIA), ki so bili stari od 4 do 17 let, je bila povprečna najmanjša koncentracija adalimumaba v serumu v stanju dinamičnega ravnovesja (vrednosti merjene od 20. do
Following the administration of a 100 mg/ m2 dose given as a one-hour infusion a mean peak plasma level of 3.7 μg/ml was obtained with a corresponding AUC of 4.6 h μg/ml.
Po aplikaciji odmerka 100 mg/m2 v enourni infuziji je bila povprečna največja koncentracija v plazmi 3,7 (ig/ml, ustrezna AUC pa 4,6 h.^g/ml.
Following the administration of a 100 mg/m2 dose given as a one-hour infusion a mean peak plasma level of 3.7 µg/ml was obtained with a corresponding AUC of 4.6 h.µg/ml.
Po aplikaciji odmerka 100 mg/m2 v enourni infuziji je bila povprečna največja koncentracija v plazmi 3,7 µg/ml, ustrezna AUC pa 4,6 h.µg/ml.
Following the administration of a 4-fold overdose of vaccine no adverse reactions other than those described under section “Adverse reactions” have been observed.
Po uporabi 4-kratnega prevelikega odmerka cepiva niso opazili drugih neželenih učinkov, razen tistih, ki so opisani v poglavju »Neželeni učinki«.
Following the administration of a double dose in chickens and ducks, no adverse reactions other than those described in section 4.6 have been observed.
Po vnosu dvojnega odmerka niso zasledili drugačnih neželenih učinkov, kot so opisani v poglavju 4.6.
Following the administration of a double dose in chickens and ducks, no adverse reactions other than those described in section 6 have been observed.
Po vnosu dvojnega odmerka pri piščancih in racah niso zasledili drugačnih neželenih učinkov, kot so opisani v poglavju 6.
Following the administration of a double dose no adverse reactions other than those described in section 4.6 have been observed.
Po vnosu dvojnega odmerka niso zasledili drugačnih neželenih učinkov, kot so opisani v poglavju 4.6.
Following the administration of a double dose of vaccine no adverse reactions other than those described in section 4.6 have been observed.
Po uporabi dvojnega odmerka cepiva niso opazili drugih neželenih reakcij, kot tistih, opisanih v poglavju 4.6.
Following the administration of a double dose of vaccine no adverse reactions other than those described in section 6 have been observed.
Po uporabi dvojnega odmerka cepiva niso opazili drugih neželenih reakcij, kot tistih, opisanih v poglavju 6.
Following the administration of a double dose of vaccine no side effects other than those described under “adverse reactions” have been observed.
Po dajanju dvojnega odmerka cepiva niso opazili neželenih učinkov, ki bi se razlikovali od učinkov, opisanih v odstavku ''neželeni učinki''.
Following the administration of a double dose of vaccine, no adverse reactions other than those described under section 4.6 have been observed.
Po dajanju dvojnega odmerka cepiva ni bilo opaziti nobenih drugih neželenih učinkov razen tistih, opisanih v poglavju 4.6.
Following the administration of a double dose of vaccine, no side effects other than those described under section 4.6 have been observed except for some depression at the day of vaccination.
Dvojni odmerek cepiva ni povzročil neželenih učinkov, ki bi se razlikovali od tistih, opisanih v poglavju 4.6, razen blage depresivnosti na dan cepljenja.
Following the administration of a double dose of vaccine, no side-effects other than those described under section 4.6 have been observed.
Dvojni odmerek cepiva ni povzročil neželenih učinkov, ki bi se razlikovali od tistih, opisanih v poglavju 4.6.
Following the administration of a double dose, no adverse reactions other than those described in section 4.6 have been observed.
Po vnosu dvojnega odmerka niso zasledili drugačnih neželenih učinkov, kot so opisani v poglavju 4.6.
Following the administration of a single 50 mg dose, the AUC0- of eltrombopag was 41% higher in subjects with mild hepatic impairment and 80% to 93% higher in subjects with moderate to severe hepatic impairment compared with healthy volunteers.
Pri uporabi enkratnega 50 mg odmerka eltrombopaga je bila pri osebah z blago okvaro jeter vrednost AUC0- eltrombopaga za 41 % večja kot pri zdravih prostovoljcih, pri osebah z zmerno do hudo okvaro jeter pa za od 80 % do 93 % večja kot pri zdravih prostovoljcih.
Following the administration of multiple doses, daptomycin AUC0-tau were 387, 438, 439 and 466 µg×hr/ml for 12-17 years, 7-11 years, 2-6 years and 1-<2 years, respectively, indicating that the daptomycin exposure was similar across the different age groups after dose adjustment based on body weight and age.
Po večkratnem odmerjanju daptomicina je bila AUC0-tau 387, 438, 439 oziroma 466 µg×h/ml za starostne skupine 12-17 let, 7-11 let, 2-6 let oziroma 1-<2 leti, kar pomeni, da je bila izpostavljenost daptomicinu po prilagajanju odmerkov na telesno maso in starost približno enaka v vseh starostnih skupinah.
Following the administration of overdoses of vaccine, no side-effects other than those described under section 4.6 have been observed.
Po dajanju prevelikih odmerkov niso ugotovili nobenih drugih stranskih učinkov razen tistih, navedenih v poglavju 4.6.
Following the administration of overdoses of vaccine, no side-effects other than those described under “Adverse reactions” have been observed.
Po dajanju prevelikih odmerkov niso ugotovili nobenih drugih stranskih učinkov razen tistih, navedenih v navedbi »Neželeni učinki ».